European Registry of Transcatheter Repair for Tricuspid Regurgitation
Launched by LMU KLINIKUM · Mar 5, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The European Registry of Transcatheter Repair for Tricuspid Regurgitation is a clinical trial that aims to understand how well different treatments work for patients with a heart condition called tricuspid regurgitation. This condition involves a valve in the heart that does not close properly, which can lead to heart failure and other serious issues. The trial will track the health and survival of patients who have undergone a procedure using specific devices designed for repairing or replacing the tricuspid valve.
To be eligible for this study, participants must be 18 years or older and have received treatment using one of the approved devices like PASCAL, TriClip, or others. The trial is currently recruiting patients, regardless of gender, and those who join can expect to be monitored closely to see how their condition improves over time. This research is important because it will help doctors better understand the best ways to treat tricuspid regurgitation and improve patient care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients treated with one of the following transcatheter devices for TV repair or replacement: PASCAL, TriClip, TricValve, Evoque, LuX-Valve
- • Age ≥ 18 years
About Lmu Klinikum
LMU Klinikum is a leading academic medical center affiliated with Ludwig Maximilian University in Munich, Germany. Renowned for its commitment to innovative research and high-quality patient care, LMU Klinikum plays a pivotal role in advancing medical science through clinical trials and translational research. With a multidisciplinary approach, the institution collaborates with various stakeholders, including healthcare professionals, researchers, and industry partners, to facilitate groundbreaking studies that aim to improve therapeutic outcomes and enhance understanding of complex diseases. Its state-of-the-art facilities and expert clinical teams ensure the highest standards of safety and efficacy in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, Bavaria, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported